StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultMay 13, 2026, 04:33 PM

BeyondSpring Reports Q1 2026 Net Loss of $2.16M; Deficit Widens

AI Summary

BeyondSpring Inc. reported a net loss attributable to the company of $2.16 million for the first quarter of 2026, a significant decline from a net income of $4.48 million in the prior year period. This shift was primarily driven by a loss from discontinued operations of $4.32 million in Q1 2026, compared to a gain of $3.75 million in Q1 2025 which included a gain on sale of subsidiary interests. The company's total shareholders' deficit widened to $30.35 million as of March 31, 2026.

Key Highlights

  • BeyondSpring Inc. reported a net loss of $2.16 million in Q1 2026, compared to net income of $4.48 million in Q1 2025.
  • Basic and diluted loss per share was $0.05 in Q1 2026, down from earnings per share of $0.11 in Q1 2025.
  • Loss from discontinued operations was $4.32 million in Q1 2026, versus income of $3.75 million in Q1 2025.
  • Net cash used in operating activities improved to $3.28 million in Q1 2026 from $4.20 million in Q1 2025.
  • Total shareholders' deficit increased to $30.35 million as of March 31, 2026, from $23.99 million at December 31, 2025.
  • Cash and cash equivalents from continuing operations decreased to $4.04 million as of March 31, 2026.
  • Research and development expenses increased to $1.08 million in Q1 2026 from $0.87 million in Q1 2025.
  • General and administrative expenses decreased to $1.16 million in Q1 2026 from $1.74 million in Q1 2025.